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We May Develop Medications Effective Against COVID-19,
but Can We Distribute Them Equitably?
Daniel J. Kersten1,2 and Amgad N. Makaryus1,3,*

There has been signiﬁcant press regarding possible pharmaceutical agents with efﬁcacy against the novel coronavirus disease 2019 (COVID-19). These medications may
provide critically ill patients a greater chance of recovering from the virus. As the COVID-19 pandemic continues to escalate in the United States, concerns have been
raised that persons of lower socioeconomic status, especially in urban environments, may be at greater risk of
complications.1 These concerns are certainly valid;
lower socioeconomic status is associated with a greater
incidence of chronic illnesses and poorer access to
health insurance and to medical care.2–4 Considering
the risks that face underprivileged urban communities,
these proposed medications could provide a vital lifeline to a particularly at-risk population. Getting these
medications to this group, however, highlights additional disparities that must be addressed for there to
be meaningful chance that these medications can
help this at-risk population.
For one, patients of lower socioeconomic status have
barriers accessing medical care in part due to limited
resource availability. These medications would require
a prescription, which would be difﬁcult considering
underserved urban areas have been consistently losing
access to medical professionals for decades.4 Places
with less than one physician per 3500 residents, classiﬁed by the federal government as ‘‘health professional
shortage areas,’’ are typically areas of urban poverty.4
Furthermore, most of hospital closures in the past 40
years were hospitals in poor urban centers and public
hospitals. The number of hospitals in U.S. major cities
dropped 46% from 1970 to 2010.4 Even if patients obtain medical care, ﬁnding a convenient pharmacy is an-

other challenge. Analysis of U.S. pharmacy closures
found that urban pharmacies at greater risk of closing
were those serving lower income communities, uninsured patients, and publicly insured patients.5
Whatever medication(s) are found to be useful, the
demand for these treatment(s) would be massive.
This will place the pharmaceutical supply chain systems under immense strain, and concerns have been
raised about how demand will be met. The U.S. Food
and Drug Administration has already advised that
there may be potential issues with obtaining supplies
for needed medical products.6 Demand for such lifesaving medication(s) would place an even greater strain
on the supply chain, thus raising prices. These increased costs would be added to the already stressed ﬁnancial situations of medical systems caring for
underserved urban communities.7 This would also affect the pharmacies in these poorer urban areas,
which are more likely to struggle with maintaining adequate supplies of pharmaceuticals.8 This may be due
to, in part, a lower density of chain pharmacies that
have better resources than independent pharmacies,
of which there is a greater density in poor urban
areas.8 It is also important to consider the element of
cost. The widespread demand coupled with limited
supply will cause prices to rise. Persons of lower socioeconomic status are less likely to have health insurance
or may have a plan that may not provide adequate
medication beneﬁts.3,9 Cost has already been identiﬁed
as a barrier to medication compliance; and additionally,
patients may adjust dosing or delay ﬁlling prescriptions
due to ﬁnancial worries.9 In a time of record unemployment and a group with limited ﬁnancial security,
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patients may need to decide between a life-saving medication or covering other necessary expenses.
For there to be maximal beneﬁt for any proven medication(s) against COVID-19, considerations must be
undertaken to address the groups at greatest risk for
complications from this virus, especially for those living
in underserved communities. First, efforts must be
made in these areas so that residents are able to access
care, whether in hospitals or clinics. This will help not
only with accessing proper care but can allow for
greater screening efforts. Second, whatever medications
are found to improve outcomes must be distributed to
areas that have the greatest need such as a higher case
burden or higher complication rates. Finally, for these
medications to be used properly, efforts must be made
to ensure that price protections are in place. If these
conditions are not addressed, areas of urban poverty
will suffer even greater consequences from COVID-19.
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